These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2501967

  • 1. Growth hormone response to overnight growth hormone-releasing hormone infusion and oral pyridostigmine in children with short stature.
    Ross RJ, Savage MO, Kirk JM, Besser GM.
    Acta Paediatr Scand Suppl; 1989; 349():114-6; discussion 123-4. PubMed ID: 2501967
    [Abstract] [Full Text] [Related]

  • 2. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM, Ross RJ, Trainer PJ, Froud AL, Davies SC, Savage MO, Besser GM.
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.
    Ross RJ, Kirk JM, Tsagarakis S, Trainer PJ, Ciccarelli E, Touzel R, Grossman A, Savage MO, Besser GM.
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):239-48. PubMed ID: 2225481
    [Abstract] [Full Text] [Related]

  • 4. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E, Imperiale E, Boffano GM, Mazza E, Bellone J, Arvat E, Procopio M, Goffi S, Barreca A, Chiabotto P.
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [Abstract] [Full Text] [Related]

  • 5. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A, Bossoni S, Bodini C, Cimino A, Pizzocolo G, Schettino M, Wehrenberg WB.
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pyridostigmine counteracts the blunted growth hormone response to growth hormone-releasing hormone of obese children.
    Loche S, Pintor C, Cappa M, Ghigo E, Puggioni R, Locatelli V, Müller EE.
    Acta Endocrinol (Copenh); 1989 May; 120(5):624-8. PubMed ID: 2499149
    [Abstract] [Full Text] [Related]

  • 10. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
    Friend K, Iranmanesh A, Login IS, Veldhuis JD.
    Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
    [Abstract] [Full Text] [Related]

  • 11. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM, Tofani A, Della Casa S, Sciuto R, Rota CA, Colasanti S, Bini A, Barini A, Barbarino A.
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [Abstract] [Full Text] [Related]

  • 12. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Feb; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 13. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL, Wallace WH, Shalet SM.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [Abstract] [Full Text] [Related]

  • 14. Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.
    Castro RC, Vieira JG, Chacra AR, Besser GM, Grossman AB, Lengyel AM.
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):385-90. PubMed ID: 2109445
    [Abstract] [Full Text] [Related]

  • 15. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF.
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A, Pumar A, Villamil F, Astorga R, Dieguez C, Casanueva FF.
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [Abstract] [Full Text] [Related]

  • 17. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [Abstract] [Full Text] [Related]

  • 18. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A, Muruais C, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [Abstract] [Full Text] [Related]

  • 19. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
    Ross RJ, Tsagarakis S, Grossman A, Nhagafoong L, Touzel RJ, Rees LH, Besser GM.
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):727-33. PubMed ID: 2901302
    [Abstract] [Full Text] [Related]

  • 20. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.